Results 181 to 190 of about 329,027 (236)

Inhibition of autotaxin activity with IOA‐289 decreases fibrosis in mouse E0771 breast tumors

International Journal of Cancer, EarlyView.
What's New? Lysophosphatidate is one of the critical mediators of fibrosis formation in the tumor microenvironment, which hinders immune surveillance and therapy. Building on their previous finding that blocking lysophosphatidate production with the autotaxin inhibitor, IOA‐289 decreased tumor growth by approximately 60%, here the authors show that ...
Xiaoyun Tang, Humayara Khan, Karolina Niewola‐Staszkowska, Frank Wuest, David N. Brindley   +4 more
wiley   +1 more source

Association of thrombomodulin with the severity of chronic kidney disease: a cross-sectional study. [PDF]

BMC Nephrol
Guo M, Cui S, Liu X, Feng J, Li M, Dong Z, Wu J, Cai G, Chen X, Li Q.   +9 more
europepmc   +1 more source

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy

International Journal of Cancer, EarlyView.
Abstract Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard‐of‐care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short‐lived, with median progression‐free ...
Brie‐Anne Mannah, John J. Park, Su Yin Lim   +2 more
wiley   +1 more source

Multiplex imaging reveals novel patterns of MRTFA/B activation in the breast cancer microenvironment. [PDF]

J Transl Med
Wilk SM, Lee K, Castillo CC, Haloul M, Gajda AM, Macias V, Wiley EL, Chen Z, Liu X, Wang X, Sverdlov M, Hoskins KF, Er EE.   +12 more
europepmc   +1 more source

Molecular subtyping and precision therapy for esophageal cancer

Interdisciplinary Medicine, Volume 3, Issue 3, May 2025.
The molecular typing of esophageal cancer based on genome, transcriptome, proteome, and multi‐omics revealed various molecular features and provided potential targets for the precision therapy. Recent trials have shown that immunotherapy or molecular targeted therapy plus chemoradiotherapy can improve overall survival and progression‐free survival in ...
Guangkun Pei, Zhuoran Liang, Bianli Gu, Linlin Shi, Ze‐Xian Liu, Shegan Gao   +5 more
wiley   +1 more source

Nano-formulations in disease therapy: designs, advances, challenges, and future directions. [PDF]

J Nanobiotechnology
Shi Y, Li X, Li Z, Sun J, Gao T, Wei G, Guo Q.   +6 more
europepmc   +1 more source

Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine

Interdisciplinary Medicine, EarlyView.
Novel biomarker emergence plays a critical role in improving CHB management. Advances in sensitive detection methods, AI, and large‐scale data platforms have independently contributed to biomarkers while driving the development of multi‐omics approaches.
Yaru Shi, Rong Fan
wiley   +1 more source

Human autoimmunity at single cell resolution in aplastic anemia before and after effective immunotherapy. [PDF]

Nat Commun
Wu Z, Gao S, Feng X, Li H, Sompairac N, Jamshidi S, Choy D, Reis RAD, Gao Q, Kajigaya S, Alemu L, Raffo DQ, Groarke EM, Kordasti S, Patel BA, Young NS.   +15 more
europepmc   +1 more source